Author/Authors :
Watanabe, Kana Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan , Fukuhara, Tatsuro Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan , Tsukita, Yoko Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan , Morita, Mami Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan , Suzuki, Aya Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan , Tanaka, Nobuyuki Division of Cancer Biology and Therapeutics - Miyagi Cancer Center Research Institute, Natori, Japan , Terasaki, Hiroshi Molecular Genetic Research Department - LSI Medience Corporation, Tokyo, Japan , Nukiwa, Toshihiro Japan Anti-Tuberculosis Association, Tokyo, Japan , Maemondo, Makoto Department of Respiratory Medicine - Miyagi Cancer Center, Nodayama, Medeshima-Shiote, Natori, Japan
Abstract :
Introduction. Rebiopsies have become more crucial in non-small cell lung cancer (NSCLC). Instead of invasive biopsies,
development of collecting biological data of the tumor from blood samples is expected. We conducted a prospective study to assess
the feasibility of detection of epidermal growth factor receptor (EGFR) mutation in plasma samples. Method. NSCLC patients
harboring EGFR activating mutations, who were going to receive EGFR-tyrosine kinase inhibitors (TKIs) as first-line treatment,
were enrolled in this study. Plasma EGFR activating mutations and the T790M resistance mutation were analyzed by an improved
PNA-LNA PCR clamp method, characterized by a 10-fold or more sensitivity compared with the original methods. Result. Six
patients with wild-type EGFR and 24 patients with EGFR mutations were enrolled in this study. Pretreatment plasma samples
achieved sensitivity of 79%. The 6 patients with wild-type EGFR were all negative for plasma EGFR mutations. At the time of
disease progression, plasma T790M mutation was detected in 8 of 16 cases. Absence of T790M before and during TKI treatment
and disappearance of activating mutations during TKI treatment were considered as predictors of EGFR-TKIs efficacy. Conclusion.
We were able to detect EGFR mutations in plasma samples by using an improved PNA-LNA PCR clamp method.
